Declaratory Judgments Unavoidable For Biosimilar Applicants
Since the enactment of the Biologics Price Competition and Innovation Act, debate has brewed over the type and amount of information a biosimilar applicant must disclose under its prescribed information exchange...To view the full article, register now.
Already a subscriber? Click here to view full article